Drugs / JNJ-69095897
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04920578 | Jun 2021 → Jan 2023 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-69095897 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04920578 ↗ |
| Route | Oral | “administered orally” NCT04920578 ↗ |